170 related articles for article (PubMed ID: 33899544)
1. Systemic analysis of the expression levels and prognosis of breast cancer-related cadherins.
Xu M; Liu C; Pu L; Lai J; Li J; Ning Q; Liu X; Deng S
Exp Biol Med (Maywood); 2021 Aug; 246(15):1706-1720. PubMed ID: 33899544
[TBL] [Abstract][Full Text] [Related]
2. Dissection of the APCCdh1-Skp2 cascade in breast cancer.
Fujita T; Liu W; Doihara H; Date H; Wan Y
Clin Cancer Res; 2008 Apr; 14(7):1966-75. PubMed ID: 18381934
[TBL] [Abstract][Full Text] [Related]
3. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Biomarkers Associated With the Prognosis and Potential Pathogenesis of Breast Cancer via Integrated Bioinformatics Analysis.
Wu M; Li Q; Wang H
Technol Cancer Res Treat; 2021; 20():1533033821992081. PubMed ID: 33550915
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
6. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
7. A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.
Mao W; Zhou J; Hu J; Zhao K; Fu Z; Wang J; Mao K
Front Public Health; 2022; 10():969070. PubMed ID: 36051999
[TBL] [Abstract][Full Text] [Related]
8. P-cadherin as prognostic factor for loco-regional relapse in breast cancer.
Faria G; Cardoso MJ; Martins D; Bettencourt H; Amendoeira I; Schimitt F
Acta Med Port; 2012; 25(2):97-105. PubMed ID: 22985920
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of PLKs expression and prognosis in breast cancer.
Jiawei W; Xiajun B; Tian S; Xuzheng G; Zhenwang Z
Cancer Genet; 2022 Nov; 268-269():83-92. PubMed ID: 36206661
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline.
Zhu C; Feng X; Ye G; Huang T
Medicine (Baltimore); 2017 Apr; 96(16):e6650. PubMed ID: 28422868
[TBL] [Abstract][Full Text] [Related]
11. Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.
Lin YL; Wang YL; Fu XL; Li WP; Wang YH; Ma JG
Oncotarget; 2016 May; 7(19):28384-92. PubMed ID: 27070091
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of P-cadherin is an indicator of poor prognosis in breast cancer: a systematic review and meta-analysis.
Sridhar S; Rajesh C; Jishnu PV; Jayaram P; Kabekkodu SP
Breast Cancer Res Treat; 2020 Jan; 179(2):301-313. PubMed ID: 31664550
[TBL] [Abstract][Full Text] [Related]
13. Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients.
Wu CC; Ekanem TI; Phan NN; Loan DTT; Hou SY; Lee KH; Wang CY
Int J Med Sci; 2020; 17(18):3112-3124. PubMed ID: 33173433
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and immunological value of
Wang J; Liu Y; Zhang S
Aging (Albany NY); 2021 Jul; 13(13):16904-16921. PubMed ID: 34228637
[TBL] [Abstract][Full Text] [Related]
15. Identification of LCN1 as a Potential Biomarker for Breast Cancer by Bioinformatic Analysis.
Yang Y; Li F; Luo X; Jia B; Zhao X; Liu B; Gao R; Yang L; Wei W; He J
DNA Cell Biol; 2019 Oct; 38(10):1088-1099. PubMed ID: 31424267
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of prognostic significance of cadherin (CDH) gene family in breast cancer.
Ku SC; Liu HL; Su CY; Yeh IJ; Yen MC; Anuraga G; Ta HDK; Chiao CC; Xuan DTM; Prayugo FB; Wang WJ; Wang CY
Aging (Albany NY); 2022 Oct; 14(20):8498-8567. PubMed ID: 36315446
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the Expression of
Chen C; Chen S; Pang L; Yan H; Luo M; Zhao Q; Lai J; Li H
Biomed Res Int; 2020; 2020():6412593. PubMed ID: 32104702
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of CDH1 or CTNNB1 affects poor prognosis of patients with esophageal cancer.
Ishiguro H; Wakasugi T; Terashita Y; Sakamoto N; Tanaka T; Mizoguchi K; Sagawa H; Okubo T; Takeyama H
World J Surg Oncol; 2016 Sep; 14(1):240. PubMed ID: 27600761
[TBL] [Abstract][Full Text] [Related]
20. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
